EA201401097A1 - Способ оценки жизнеспособности вирусов, обладающих лимфотропизмом - Google Patents

Способ оценки жизнеспособности вирусов, обладающих лимфотропизмом

Info

Publication number
EA201401097A1
EA201401097A1 EA201401097A EA201401097A EA201401097A1 EA 201401097 A1 EA201401097 A1 EA 201401097A1 EA 201401097 A EA201401097 A EA 201401097A EA 201401097 A EA201401097 A EA 201401097A EA 201401097 A1 EA201401097 A1 EA 201401097A1
Authority
EA
Eurasian Patent Office
Prior art keywords
viruses
lymphotropism
lymphocytes
cytoplasm
pcr
Prior art date
Application number
EA201401097A
Other languages
English (en)
Other versions
EA032036B1 (ru
Inventor
Нариман ГУЛЯМОВ
Original Assignee
Общество С Ограниченной Ответственностью "New Medical Technologies"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "New Medical Technologies" filed Critical Общество С Ограниченной Ответственностью "New Medical Technologies"
Publication of EA201401097A1 publication Critical patent/EA201401097A1/ru
Publication of EA032036B1 publication Critical patent/EA032036B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D

Abstract

Использование: медицина, биотехнология. Задача: повышение достоверности определения инфицированности вирусами, обладающими лимфотропизмом, исключение ложноотрицательных реакций при тестировании крови на наличие лимфотропных вирусов при ИФА и ПЦР-исследовании, обнаружение вирусов, обладающих лимфотропизмом, в биологическом материале с концентрацией вирусных частиц ниже порога чувствительности методов ИФА или ПЦР. Сущность изобретения: способ оценки жизнеспособности вирусов, обладающих лимфотропизмом, включает забор биологического материала, определение наличия в нем РНК или ДНК вирусов путем проведения полимеразной цепной реакции (ПЦР-реакция). При этом дополнительно из крови здоровых людей получают взвесь лимфоцитов, к которым добавляется равный объем биологического материала. После чего смесь перемешивают, инкубируют при температуре 37°С в течение 6-8 ч, производят отмывание лимфоцитов от плазмы и разрушение лимфоцитов. Цитоплазму лимфоцитов подвергают ПЦР-исследованию. Обнаружение в цитоплазме лимфоцитов РНК или ДНК вирусов свидетельствует о сохранении жизнеспособности вирусов. Отсутствие в цитоплазме лимфоцитов РНК или ДНК вирусов свидетельствует об инактивации вирусов.
EA201401097A 2012-06-18 2013-05-21 Способ оценки жизнеспособности вирусов, обладающих лимфотропизмом EA032036B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
UZIA20120233 2012-06-18
PCT/UZ2013/000001 WO2013192636A1 (ru) 2012-06-18 2013-05-21 Способ оценки жизнеспособности вирусов, обладающих лимфотропизмом

Publications (2)

Publication Number Publication Date
EA201401097A1 true EA201401097A1 (ru) 2015-04-30
EA032036B1 EA032036B1 (ru) 2019-03-29

Family

ID=84083119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401097A EA032036B1 (ru) 2012-06-18 2013-05-21 Способ оценки жизнеспособности вирусов, обладающих лимфотропизмом

Country Status (10)

Country Link
US (7) US9879329B2 (ru)
EP (3) EP3517628A1 (ru)
KR (2) KR20140127864A (ru)
CN (1) CN104066848A (ru)
AP (1) AP2014008052A0 (ru)
EA (1) EA032036B1 (ru)
IL (1) IL235962B (ru)
IN (1) IN2014DN10904A (ru)
WO (1) WO2013192636A1 (ru)
ZA (1) ZA201405954B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140127864A (ko) * 2012-06-18 2014-11-04 유한회사 뉴메디컬 테크놀로지스 림프조직 친화성 바이러스의 생존능 평가 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674680A (en) * 1994-01-31 1997-10-07 The Rockefeller University Methods for the prognosis and monitoring of AIDS
US20090176202A1 (en) * 2007-03-23 2009-07-09 Rigel Pharmaceuticals, Inc. Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIV
KR20140127864A (ko) * 2012-06-18 2014-11-04 유한회사 뉴메디컬 테크놀로지스 림프조직 친화성 바이러스의 생존능 평가 방법

Also Published As

Publication number Publication date
US9957579B2 (en) 2018-05-01
EP3517628A1 (en) 2019-07-31
EP2818558A1 (en) 2014-12-31
US9873922B2 (en) 2018-01-23
US10570466B2 (en) 2020-02-25
EP2818558A4 (en) 2015-09-23
KR20160139059A (ko) 2016-12-06
US20230078548A1 (en) 2023-03-16
AP2014008052A0 (ru) 2014-11-30
EP3517627A1 (en) 2019-07-31
CN104066848A (zh) 2014-09-24
EP2818558B1 (en) 2019-07-17
US20180245167A1 (en) 2018-08-30
US9879329B2 (en) 2018-01-30
WO2013192636A1 (ru) 2013-12-27
US11505837B2 (en) 2022-11-22
KR20140127864A (ko) 2014-11-04
US20160369325A1 (en) 2016-12-22
IN2014DN10904A (ru) 2015-09-11
US10920289B2 (en) 2021-02-16
US20170073779A1 (en) 2017-03-16
IL235962B (en) 2018-07-31
US20200190606A1 (en) 2020-06-18
ZA201405954B (en) 2015-11-25
IL235962A0 (en) 2015-01-29
US20150125852A1 (en) 2015-05-07
EA032036B1 (ru) 2019-03-29
US20210140001A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
Moon et al. Colorimetric detection of SARS-CoV-2 and drug-resistant pH1N1 using CRISPR/dCas9
CY1119972T1 (el) Προσδιορισμος για αντισωματα ιου jc
BR112012021202A2 (pt) aparelho e metodos para preparacao, reacao e deteccao integradas de amostras
MX2011008970A (es) Sondas e iniciadores para la deteccion de chikungunya.
BRPI0518405A2 (pt) detecÇço de vÍrus papiloma humano (hpv) utilizando sondas de Ácido nuclÉico, microcontas e separador de cÉlulas ativado fluorescente (facs)
EP3239305A3 (en) Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
RU2014114838A (ru) Способы контроля восприимчивости анти-smad7 терапии
MX2012002411A (es) Metodos de ensayo para el mdv-1.
Sun et al. Droplet-microfluidics-assisted sequencing of HIV proviruses and their integration sites in cells from people on antiretroviral therapy
RU2014122607A (ru) Способы определения восприимчивости пациента к внутрибольничной инфекции и составления прогноза развития септического синдрома
Genshaft et al. Clinical implementation of single-cell RNA sequencing using liver fine needle aspirate tissue sampling and centralized processing captures compartment specific immuno-diversity
Sassu et al. Development and evaluation of a real-time PCR panel for the detection of 20 immune markers in cattle and sheep
EA201401097A1 (ru) Способ оценки жизнеспособности вирусов, обладающих лимфотропизмом
Panda et al. In vitro culture of human PBMCs
Rimmer et al. Validation of high throughput methods for tissue disruption and nucleic acid extraction for ranaviruses (family Iridoviridae)
RU2550257C2 (ru) СПОСОБ ДИФФЕРЕНЦИАЦИИ ТИПИЧНЫХ И АТИПИЧНЫХ ШТАММОВ Yersinia pestis СРЕДНЕВЕКОВОГО БИОВАРА МЕТОДОМ ПЦР С ГИБРИДИЗАЦИОННО-ФЛУОРЕСЦЕНТНЫМ УЧЕТОМ РЕЗУЛЬТАТОВ
CN103789430A (zh) 一种快速检测血液中附红细胞体、钩端螺旋体、弓形虫的试剂盒及应用
RU2565554C2 (ru) СПОСОБ ДИФФЕРЕНЦИАЦИИ БИОВАРОВ И ГЕНОВАРИАНТОВ ШТАММОВ Yersinia pestis ОСНОВНОГО ПОДВИДА С ПОМОЩЬЮ ПОЛИМЕРАЗНОЙ ЦЕПНОЙ РЕАКЦИИ
RU2012139719A (ru) Способ количественного определения фиксированного вируса бешенства штамма "москва 3253" при производстве гетерологичного антирабического иммуноглобулина
Shukla et al. Vitality of proteinase K in rRTPCR detection of SARS-CoV2 bypassing RNA extraction
Sun et al. Droplet microfluidic sequencing of HIV genomes and integration sites
PL401061A1 (pl) Nowe sondy do wykrywania bakterii z gatunku Acinetobacter baumannii, oligonukleotydowe startery, sposób oraz zestaw do analizy próbek medycznych i środowiskowych
Gauthier et al. Nanopore Metagenomic Sequencing for Detection and Characterization of SARS-CoV-2 in Clinical Samples (preprint)
RU2012144762A (ru) Способ тестирования вируса лейкоза крупного рогатого скота с использованием пцр-диагностики с флуоресцентной формой детекции
US20160024602A1 (en) Methods of Evaluating a Cellular Sample for Latent Cellular Replication Competent HIV-1, and Compositions and Kits for Use in Practicing the Same